Vaxcyte, Inc. (PCVX) Financial Statements

Executive TeamFinancials
Shareholders

Vaxcyte financial statements at a glance

Vaxcyte reported revenue of $0 for fiscal year 2025 (ended December 31, 2025). Net income was -$766.63 million, and diluted earnings per share were -$5.63.

At the end of fiscal year 2025 it had total assets of $3.00 billion, total liabilities of $317.21 million and shareholders' equity of $2.69 billion, with cash and short-term investments of $1.56 billion and total debt of $117.48 million.

Its operations brought in -$655.58 million of cash; capital spending was $56.97 million, leaving free cash flow of -$712.55 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

PCVX logo

Vaxcyte, Inc.

PCVXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
0
Prev Year: 0
Diluted NI Available to Com Stockholders
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Operating Expense
923.67M
Prev Year: 569.55M
YoY: +62.2%
Selling General and Administrative
129.37M
Prev Year: 92.90M
YoY: +39.3%
General and Administrative Expense
129.37M
Prev Year: 92.90M
YoY: +39.3%
Other General and Administrative
129.37M
Prev Year: 92.90M
YoY: +39.3%
Research and Development
794.31M
Prev Year: 476.64M
YoY: +66.6%
Operating Income
-923.67M
Prev Year: -569.55M
YoY: -62.2%
Net Non Operating Interest Income Expense
119.72M
Prev Year: 109.99M
YoY: +8.8%
Non-operating Interest Income
119.72M
Prev Year: 109.99M
YoY: +8.8%
Other Income Expense
37.33M
Prev Year: -4.38M
YoY: +953.2%
Other Non-operating Income (expense)
37.33M
Prev Year: -4.38M
YoY: +953.2%
Gain on Sale of Securities
-
Pre-tax Income
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Net Income Common Stockholders
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Net Income
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Net Income Including Non-Controlling Interests
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Net Income from Continuing Operations
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Basic EPS
-5.63
Prev Year: -3.8
YoY: -48.2%
Diluted EPS
-5.63
Prev Year: -3.8
YoY: -48.2%
Weighted Average Shares (basic)
136.09M
Prev Year: 122.00M
YoY: +11.6%
Weighted Average Shares (diluted)
136.09M
Prev Year: 122.00M
YoY: +11.6%
Net Income from Continuing and Discontinued Operation
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Normalized Income
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Interest Income
119.72M
Prev Year: 109.99M
YoY: +8.8%
Net Interest Income
119.72M
Prev Year: 109.99M
YoY: +8.8%
EBIT
-923.67M
Prev Year: -463.93M
YoY: -99.1%
EBITDA
-898.82M
Prev Year: -448.08M
YoY: -100.6%
Reconciled Depreciation
24.86M
Prev Year: 15.85M
YoY: +56.9%
Interest Expense
-
Prev Year: 0
Net Income from Continuing Operation Net Minority Interest
-766.63M
Prev Year: -463.93M
YoY: -65.2%
Normalized EBITDA
-898.82M
Prev Year: -448.08M
YoY: -100.6%
Total Expenses
923.67M
Prev Year: 569.55M
YoY: +62.2%
Total Operating Income as Reported
-923.67M
Prev Year: -569.55M
YoY: -62.2%
Values in USD

Vaxcyte key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$0$0$0$0$0
Operating income-$923.7M-$569.5M-$393.0M-$209.3M-$102.1M
Net income-$766.6M-$463.9M-$402.3M-$223.5M-$100.1M
Diluted EPS-$5.63-$3.80-$4.14-$3.44-$1.93
Total assets$3.0B$3.5B$1.4B$1.0B$324.3M
Total liabilities$317.2M$205.5M$167.4M$52.6M$40.3M
Shareholders' equity$2.7B$3.3B$1.2B$953.6M$284.0M
Cash and short-term investments$1.6B$1.7B$1.1B$931.4M$246.0M
Total debt$117.5M$71.1M$29.2M$17.9M$16.8M
Operating cash flow-$655.6M-$452.6M-$296.8M-$170.6M-$121.4M
Capital spending$57.0M$119.2M$67.9M$5.8M$6.6M
Free cash flow-$712.6M-$571.8M-$364.7M-$176.4M-$127.9M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2018.

Questions and answers

What was Vaxcyte's revenue in fiscal year 2025?

$0.

How much profit does Vaxcyte make?

Vaxcyte reported net income of -$766.63 million for fiscal year 2025; operating income was -$923.68 million.

How much cash and debt does Vaxcyte have?

At the end of fiscal year 2025: cash and short-term investments of $1.56 billion and total debt of $117.48 million.

What is Vaxcyte's free cash flow?

-$712.55 million in fiscal year 2025 (operating cash flow of -$655.58 million minus capital spending of $56.97 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube